[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584894":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":93,"collaborators":10,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":10,"enrollmentInfo":104,"targetDuration":10,"studyType":107,"phases":10,"briefSummary":108,"conditions":109,"keywords":116,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients affected by Monoclonal plasma cell disorders",null,"Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Multiple Myeloma (MM).",[13],"Diagnostic Test: Whole Body-Magnetic Resonance Imaging (WB-MRI)",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients affected by advanced prostate cancer (APC) or advanced breast cancer (ABC)","Patients affected by advanced prostate (APC) or breast cancer (ABC) with high suspicious of metastasis particularly in case of diagnostic doubt in other imaging methods (Computed tomography (CT), Positron Emission Computed Tomography (PET\u002FCT), Bone Scintigraphy (BS)).",[13],{"label":19,"type":10,"description":19,"interventionNames":20},"Patients affected by Lymphomas.",[13],[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"DIAGNOSTIC_TEST","Whole Body-Magnetic Resonance Imaging (WB-MRI)","This is a non-pharmacological, observational, prospective, study. Each patient will undergo quantitative WB-MRI as per clinical routine. WB-MRI may be performed:\n\n* at staging\n* at follow-up Disease progression is defined by clinicians taking into account all imaging modalities and clinicolaboratorial data available for the patients.",[19,9,15],[28],{"name":29,"affiliation":30,"role":31},"Alice Rossi","IRCCS Istituto Romagnolo per lo Studio dei Tumori \"Dino Amadori\" - IRST S.r.l.","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Oriana Nanni","CONTACT","+390543739266","cc.ubsc@irst.emr.it",{"name":39,"role":35,"phone":40,"phoneExt":10,"email":37},"Bernadette Vertogen","+390544286058",[42,62,76],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"IRCCS - Azienda Ospedaliero-Universitaria di Bologna - Policlinico di S. Orsola","RECRUITING","Bologna","BO","40138","Italy","IT",{"type":51,"coordinates":52},"Point",[53,54],11.33875,44.49381,{"lat":54,"lon":53},[57,60],{"name":58,"role":35,"phone":10,"phoneExt":10,"email":59},"Stefano Brocchi","stefano.brocchi@aosp.bo.it",{"name":61,"role":31,"phone":10,"phoneExt":10,"email":10},"Stefano Brocchi, MD",{"facility":30,"status":44,"city":63,"state":64,"zip":65,"country":48,"countryCode":49,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Meldola","FC","47014",{"type":51,"coordinates":67},[68,69],12.0626,44.12775,{"lat":69,"lon":68},[72,74],{"name":29,"role":35,"phone":10,"phoneExt":10,"email":73},"alice.rossi@irst.emr.it",{"name":75,"role":31,"phone":10,"phoneExt":10,"email":10},"Alice Rossi, MD",{"facility":77,"status":78,"city":79,"state":80,"zip":81,"country":48,"countryCode":49,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"IRCCS Istituto Europeo di Oncologia S.r.l.","NOT_YET_RECRUITING","Milan","MI","20141",{"type":51,"coordinates":83},[84,85],12.59836,42.78235,{"lat":85,"lon":84},[88,91],{"name":89,"role":35,"phone":10,"phoneExt":10,"email":90},"Giuseppe Petralia","giuseppe.petralia@ieo.it",{"name":92,"role":31,"phone":10,"phoneExt":10,"email":10},"Giuseppe Petralia, MD",{"type":94,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100584894","whole-body-mri-in-oncology-100584894",false,"NCT06895291","Whole Body MRI in Oncology","ONCO-MRI","Inclusion Criteria:\n\n* Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above.\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged ≥ 18 years.\n* Life expectancy greater than 3 months.\n\nExclusion Criteria:\n\n* Patients with MRI-unsafe prostheses and devices.\n* Patients whose tests are of suboptimal quality, or whose test has been suspended, or is incomplete.","ALL","18 Years",{"count":105,"type":106},1000,"ESTIMATED","OBSERVATIONAL","Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures\u002Fpatient visits in comparison with the usual clinical practice are planned for the study.",[110,111,112,113,114,115],"Lymphoma","Advanced Prostate Cancer","Advanced Breast Cancer","Monoclonal Gammopathy of Undetermined Significance","Smoldering Multiple Myeloma","Multiple Myeloma",[113,117,118,112,111,110,119],"Smoldering multiple myeloma","Multiple myeloma","Whole Body-Magnetic Resonance Imaging","2025-03-25",{"date":122,"type":123},"2025-03-30","ACTUAL",{"date":125,"type":123},"2023-10-26",{"date":127,"type":106},"2031-10",{"name":5,"class":6},3]